title: [Selective blockade of the mutated BRAF leads to a survival benefit in patients with metastatic melanoma].
authors: Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen Hufelandstr. 55, D-45122 Essen. dirk.schadendorf@uk-essen.de
authors: Dirk
authors: D
authors: Schadendorf
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D020022:Genetic Predisposition to Disease / Q000453:epidemiology / Q000235:genetics; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary*; D009154:Mutation / Q000235:genetics; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality*; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf